Semaglutide for Smoking Cessation in Patients With Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07059377

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07059377
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07059377. Randomized; no masking; primary purpose treatment. Start 2026-02-13 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide for Smoking Cessation in Patients With Diabetes
Acronym
GLP1-SC
Condition
Diabetes Mellitus, Type 2
Condition
Nicotine Addiction
Condition
Tobacco Dependence
Intervention (Drug)
Semaglutide
Intervention (Drug)
Nicotine replacement
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)

Record details

Record id
cardio:ct-nct07059377
Content hash
6f6f76064bd2125adeec410cf26d1aa305224f4c174d934ebe948f3d66e82ebf